Turn Therapeutics (TTRX) Net Cash Flow (2024 - 2026)

Turn Therapeutics' Net Cash Flow history runs 3 years deep, the most recent figure standing at $6.2 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 782.0% year-over-year to $6.2 million; the TTM figure through Mar 2026 stood at $8.8 million (changed N/A YoY), while the FY2025 annual figure was $4.2 million, up 1451.0% from the prior year.
• Net Cash Flow for Q1 2026 stood at $6.2 million, up from $1.9 million in the prior quarter.
• The five-year high for Net Cash Flow was $6.2 million in Q1 2026, with the low at $83819.0 in Q4 2024.
• The 3-year median for Net Cash Flow is $1.3 million (2025), against an average of $2.2 million.
• The sharpest annual moves came in 2025 and 2026: Net Cash Flow soared 2210.04% in 2025, then surged 782.0% in 2026.
• Turn Therapeutics' Net Cash Flow stood at $83819.0 in 2024, then jumped by 2210.04% to $1.9 million in 2025, then surged by 218.88% to $6.2 million in 2026.
• Business Quant data shows TTRX's Net Cash Flow at $6.2 million in Q1 2026, $1.9 million in Q4 2025, and $700034.0 in Q1 2025.